- Raised $18M Series A, Jan 2026
- Raised $5.1M Seed round led by Cancer Focus Fund, Sep 2024
- Raised $10M Pre-Seed round, Nov 2019
About
Starget Pharma is a clinical-stage radiopharmaceutical company developing next-generation peptide radioligand therapies (RLTs) for cancer, with operations in the U.S. and Israel. Its AI-driven platform integrates peptide design, theranostic imaging, and rapid clinical insight to advance novel radioligand therapies with first- and best-in-class potential. The company's research focuses on developing molecules that serve as vectors for the targeted transfer of radioactive isotopes to cancerous tumors for diagnosis and treatment, minimizing damage to healthy tissue. Starget Pharma's proprietary in silico, AI-driven platform leverages computational modeling and data-driven prediction to rapidly identify and prioritize radioligand therapies (RLT) candidates, maximizing speed and efficiency. The company expects to begin advanced clinical trials in collaboration with MD Anderson Cancer Center for sarcoma, skin cancer, and neuroendocrine tumors, and another drug candidate for breast and prostate cancer is expected to enter clinical trials in Australia.
Funding history · 3 rounds · $33.1M total
Headcount over time
Q&A
- What is Starget Pharma's primary focus?
- Starget Pharma is a clinical-stage radiopharmaceutical company focused on developing next-generation peptide radioligand therapies (RLTs) for cancer, utilizing an AI-driven platform for precision oncology.
- When was Starget Pharma founded?
- Starget Pharma was founded in July 2019.
- How many employees does Starget Pharma have?
- Starget Pharma has 11-50 employees.
- What was Starget Pharma's most recent funding round?
- In February 2026, Starget Pharma closed an A Round, raising $18,000,000. Lead investors included Ilex Medical and Louisiana Growth Fund.
- Which investors participated in Starget Pharma's Seed round in October 2024?
- In October 2024, Starget Pharma received a $5,100,000 Seed investment from Cancer Focus Fund.
- What is the total amount of funding Starget Pharma has raised to date?
- Starget Pharma has raised a total of $38,000,000 to date.
- What clinical trials is Starget Pharma expected to begin?
- Starget Pharma expects to begin advanced clinical trials in collaboration with MD Anderson Cancer Center for sarcoma, skin cancer, and neuroendocrine tumors. Another drug candidate for breast and prostate cancer is expected to enter clinical trials in Australia.
- Who are the co-founders of Starget Pharma?
- The co-founders of Starget Pharma are Sigal Kalmanson Cusnir, who also serves as CEO, and Ronen Kalmanson, who is the Chairman.
Team · 2
Sectors & technology
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | stargetpharma.com/ |
|---|---|
| linkedin.com/company/34613787 |
Identifiers & details
| Legal name | STARGET PHARMA LTD |
|---|---|
| Founded | 2019-7 |
| Employees (exact) | 20 |
Radar intelligence
Patents
| EPO | 3 |
|---|
Web history (Wayback)
| Domain | stargetpharma.com |
|---|
Certificate / subdomain footprint
| Subdomains | 4 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 516057411 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2019-07-17 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2026 |
| Active charges / liens | 0 |
| Registry events | 5 — other (1), annual_report (2), people (2) |
| Registered address | שניר 26 רמת השרון |
Recent registry events
| Date | Event |
|---|---|
| 2026-06-29 | שינוי בתקנון |
| 2026-02-25 | דו~ח שנתי-הוספת בעל תפקיד |
| 2026-02-25 | דו~ח שנתי-הקצאת מניות |
| 2025-09-08 | עדכון דירקטורים-הוספת דירקטור |
| 2025-09-08 | עדכון דירקטורים-הסרת דירקטור |